With the development of China immune therapy, the requirement for the standardization of it has been increased within industry. The safety of immune therapy depends on the cell itself and the cell’s preparation. Therefore, the quality management of cell preparation is a vital part of the safety.

In order to fill the blank of industrial standard, CMBA organized experts of immune therapy to draft the Standard of Quality Management of Immune Cell Product Preparation during more than one recent year. After holding several time meetings to revise the draft, the opinion soliciting draft was published and the opinions were collected. Following the final revising, the standard has been issued right now which the organizations that make immune cell can refer to. The detail of the standard can be tracked on CMBA Chinese website: http://www.cmba.org.cn/common/index.aspx?nodeid=283